John A. Orwin - 12 May 2026 Form 4/A - Amendment Insider Report for First Tracks Biotherapeutics, Inc. (TRAX)

Reporting relationship: Director
Issuer ticker: TRAX
Reported as of: 12 May 2026
Net transaction value: $0
SEC form: 4/A - Amendment
Accepted by SEC: 12 Jun 2026, 16:07:42 UTC
Original report date: 14 May 2026
Prior SEC filing: 22 Apr 2026
Next SEC filing: 21 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Ajim Tamboli, Attorney-in-Fact

Key filing fact

John A. Orwin filed Form 4/A - Amendment for First Tracks Biotherapeutics, Inc. (TRAX) on 12 Jun 2026.

Key facts

This page summarizes John A. Orwin's Form 4/A - Amendment filing for First Tracks Biotherapeutics, Inc. (TRAX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 12 Jun 2026, 16:07.

Change

Previous filing in this sequence was filed on 22 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reporting Owners (1)

CIK 0001477384 Primary reporting owner

Orwin John A

Relationship: Director
Address: 10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO
Signature: /s/ Ajim Tamboli, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TRAX transaction Derivative

Restricted Stock Unit

Award

Transaction value
Shares: +2,500
Change %
Price: $0.000000^*
Shares after: 2,500
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price
Footnotes: F1, F2

TRAX transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +7,000
Change %
Price: $0.000000^*
Shares after: 7,000
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 7,000
Exercise price: $17.81
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.

Footnote F2

The RSUs vests as to 100% of the total RSUs on the date of the Issuer's 2027 annual meeting of shareholders, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F3

The stock option vests as to 1/12 of the total shares monthly commencing on June 12, 2026 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

SEC remarks

This amended Form 4, as originally filed on May 14, 2026, is being filed to correct the amount of stock options and RSUs granted to the Reporting Person. This Form 4 amendment updates both equity awards to reflect 7,000 stock options and 2,500 RSUs originally granted to the Reporting Person on May 12, 2026.